Blue Owl Capital backed the $4bn acquisition of PCI Pharma Services, a leading provider of pharmaceutical packaging and clinical trial solutions.
The deal was led by Kohlberg & Company, with Blue Owl providing strategic financing to support the transaction.
PCI Pharma Services, headquartered in Philadelphia, delivers packaging, clinical trial support, and supply chain solutions to pharmaceutical and biotech companies. Operating across the US, Europe, and Asia, PCI plays a vital role in accelerating drug development and ensuring timely delivery to patients worldwide.
The acquisition highlights the increasing demand for efficient pharmaceutical supply chain solutions amid growing global healthcare needs. Blue Owl’s investment aligns with its strategy to support resilient businesses in essential sectors, reflecting the firm’s confidence in PCI’s growth potential and its role in advancing global health innovation.
This transaction underscores the importance of strategic partnerships between private equity firms and alternative asset managers in funding large-scale deals within critical industries. Blue Owl’s involvement reaffirms its position as a trusted partner for transformative investments in high-growth sectors.
Source: Private Equity Wire
Can’t stop reading? Read more
“12 is the new 5”: private equity’s shift from structure to substance
“12 is the new 5”: private equity’s shift from structure to substance After a decade defined by...
Advent exits OLAPLEX in $1.4bn sale to Henkel as premium beauty M&A accelerates
Advent exits OLAPLEX in $1.4bn sale to Henkel as premium beauty M&A accelerates Advent has...
Alterra backs General Atlantic in Wireless Logic deal as Middle East investment continues
Alterra backs General Atlantic in Wireless Logic deal as Middle East investment continues Alterra...